Thanks for weighing in. The difference between your forecasts and mine is tantamount to round-off error. For all practical purposes, you, ‘dewophile’, and I are in agreement regarding the pricing dynamics in the US HCV market.
GILD pretty much confirmed Sofosbuvir/Ledipasvir FDC price will be $95,000 - $97,000 for 12-week regimen. GILD could have hired us as consultants :-). We were very close in our predictions many months ago.
Market Data 
Markets 
AI
